drugset / Trial / NCT00514371
A Study of Tanespimycin (KOS-953) in Patients With Relapsed-refractory Multiple Myeloma
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a phase 2/3, open label trial for patients with relapsed-refractory multiple myeloma. Study agent is tanespimycin (KOS-953), at three different dose levels in combination with a fixed dose of bortezomib.
Timeline
- Start
- 2007-08
- Primary completion
- 2009-02
- Completion
- 2009-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | tanespimycin | Unknown | — | — |
| Background | Bortezomib | Small molecule | — | — |